Par Pharmaceutical Inc, an operating company of Ireland-based Endo International plc (NASDAQ: ENDP) announced on Tuesday that it has started shipping the first generic version of Merz's CUVPOSA (glycopyrrolate) 1mg/5mL oral solution in the United States.
This move is subsequent to the final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application. According to IQVIA, CUVPOSA sales were approximately USD27m for the 12 months ended 31 October 2021.
Jon Holden, senior vice president and general manager, Generics at Endo, said, 'We're proud to provide families with a generic option of this important medication. Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products--and our reputation for dependable quality is an especially essential factor when treating children.'
CUVPOSA is a registered trademark of Merz Pharmaceuticals LLC.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling